Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cancer Biology and Medicine

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Gastroenterology

Show all topics

DOI

10.20892/j.issn.2095-3941.2023.0423

License

CC-BY-NC

Other Formats

PDF